课题基金 / 基金详情

Analysis of intracellular signaling cascades mediated by receptor activation and protein phosphorylation in neostriatal

Analysis of intracellular signaling cascades mediated by receptor activation and protein phosphorylation in neostriatal
新纹状体受体激活和蛋白磷酸化介导的细胞内信号级联分析
批准号:
10680727
负责人:
NISHI Akinori
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 1999

项目摘要

项目成果

NISHI Akinori的其他基金

相似基金

相关文献

中文摘要
翻译
DARPP-32是一种由多巴胺和camp调控的Mr 32kda磷酸化蛋白,是一种细胞质蛋白,在新纹状体的中等棘神经元中选择性富集。DARPP-32在Thr34残基上被camp依赖性蛋白激酶(PKA)磷酸化,转化为一种有效的蛋白磷酸酶(PP) -1抑制剂。多巴胺刺激DARPP-32的磷酸化,通过抑制PP-1调节离子通道和钠泵的功能以及新纹状体神经元的兴奋性。我们研究了各种神经递质和细胞内信号系统对DARPP-32磷酸化的调控机制,得到以下结果:1。乙酰胆碱对DARPP-32磷酸化的调控:Calbachol,一种非选择性胆碱能激动剂,刺激新纹状体神经元中DARPP-32 Thr34位点的磷酸化。calbachol的作用是通过激活毒蕈碱受体介导的。更多的DARPP-32磷酸化,M1或M4,正在研究中。DARPP-32去磷酸化的调控:Phosph-Thr34在新纹状体神经元中,calcalineurin和PP-2A都能使DARPP-32去磷酸化。这两种磷酸酶协同作用维持低水平的phospho-Thr34 DARPP-32.3。细胞周期蛋白依赖性蛋白激酶5 (cdk5)磷酸化DARPP-32:在新纹状体神经元中,cdk5/p35复合物磷酸化DARPP-32的Thr75位点。DARPP-32在Thr75位点的磷酸化形式在体外和新纹状体神经元中作为PKA抑制剂起作用。DARPP-32磷酸化的调控。Thr75通过PKA:通过forskolin、cAMP类似物或多巴胺D1激动剂SKF81297刺激PKA,降低新纹状体神经元中磷酸化Thr75 DARPP-32的水平,导致PKA抑制的解除,进一步激活PKA。因此,Thr75磷酸化介导的信号级联作为PKN/phospho-Thr34、DARPP-32/PP-1和PEA/PKA底物级联的正反馈系统起作用。少
英文摘要
DARPP-32, a dopamine-and cAMP-regulated phosphoprotein of Mr 32 kDa, is a cytosolic protein that is selectively enriched in medium-sized spiny neurons in neostriatum. DARPP-32 is phosphorylated by cAMP-dependent protein kinase (PKA) at Thr34 residue, converting it into a potent inhibitor of protein phosphatase (PP) -1. Dopamine stimulates the phosphotylation of DARPP-32 and regulates the functions of ion channels and sodium pump and the excitability of neostriatal neurons by inhibiting PP-1. We studied the mechanisms of the regulation of DARPP-32 phosphorylation by various neurotransmitters and intracellular signaling systems, and obtained the following results.1. Regulation of DARPP-32 phosphorylation by acethylcholine : Calbachol, non-selective cholinergic agonist, stimulates the phosphorylation of DARPP-32 at Thr34 in neostriatal neurons. The effect of calbachol was mediated through the activation of muscarinic receptors. Isoform of muscarinic receptors involved in the regulation of … More DARPP-32 phosphorylation, M1 or M4, is under investigation.2. Regulation of DARPP-32 dephosphorylation : Phosph-Thr34 DARPP-32 is dephosphorylated by both calcineurin and PP-2A in neostriatal neurons. These two phosphatases act synergistically to maintain a low level of phospho-Thr34 DARPP-32.3. Phosphorylation of DARPP-32 by cyclin-dependent protein kinase 5 (cdk5): DARPP-l32 at Thr75 is phosphorylated by cdk5/p35 complex in neostriatal neurons. phosphorylated form of DARPP-32 at Thr75 functions as an inhibitor of PKA in vitro and in neostriatal neurons.4. Regulation of DARPP-32 phosphorylation at. Thr75 by PKA : Stimulation of PKA by forskolin, cAMP analogue or dopamine D1 agonist, SKF81297, reduced the level of phospho-Thr75 DARPP-32 in neostriatal neurons, resulting in the removal of the inhibition of PKA and further activation of PKA. Thus, the signaling cascade mediated by Thr75 phosphorylation functions as a positive feedback system for PKN/phospho-Thr34 DARPP-32/PP-1 and PEA/PKA substrate cascades. Less
期刊论文(25)
专著(0)
科研奖励(0)
会议论文
Akinori, Nishi: "Role of DARPP-32 in dopamine signal transduction in the striatum"Tanpakushitsu Kakusan Koso. 43. 102-111 (1998)
Akinori, Nishi:“DARPP-32 在纹状体多巴胺信号转导中的作用”Tanpakushitsu Kakusan Koso。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Niisi A, Snyder Gli, Fienberg AA, Fisone G, Aperia A, Nairn AC, and Greengard P: "Requirement for DARPP-32 in mediating- effect of dopamine D2 receptor activation."Eur. J. Neurosci.. 11. 2589-2592 (1999)
Niisi A、Snyder Gli、Fienberg AA、Fisone G、Aperia A、Nairn AC 和 Greengard P:“DARPP-32 介导多巴胺 D2 受体激活作用的要求”。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Nishi A et al.: "Role of calcineurin and protein phosphatase-2A in the regulation of DARPP-32 dephosphorylation in neostriatal neurons."J.Neurochem.. 72. 2015-2021 (1999)
Nishi A 等人:“钙调神经磷酸酶和蛋白磷酸酶 2A 在调节新纹状体神经元 DARPP-32 去磷酸化中的作用。”J.Neurochem.. 72. 2015-2021 (1999)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Nishi A et al.: "Role of calcineurin and protein phosphatase-2A in the regulation of DARPP-32 dephosphorylation in neostriatal neurons" Journal of Neurochemistry. 72(in press). (1999)
Nishi A 等人:“钙调神经磷酸酶和蛋白磷酸酶 2A 在调节新纹状体神经元 DARPP-32 去磷酸化中的作用”《神经化学杂志》。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
24
    Map of dopamine signaling in the neostriatum under normal and pathophysiological conditions
    • 批准号:
      18300128
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.6万
    • 财政年份:
      2006
    • 负责人:
      NISHI Akinori
    • 依托单位:
    Map of dopamine signaling in the neostriatum
    • 批准号:
      16300122
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.66万
    • 财政年份:
      2004
    • 负责人:
      NISHI Akinori
    • 依托单位:
    Molecular mechanisms of the integration of inhibitory dopaminergic inputs and excitatory glutamatergic inputs in neostriatal neurons
    • 批准号:
      14580754
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      2002
    • 负责人:
      NISHI Akinori
    • 依托单位:
    Molecular mechanisms to amplify dopamine signaling in neostriatal neurons
    国内基金
    海外基金
    DRD2/ERK/β-catenin信号联合Dopamine/ERK/TH调节环介导慢性应激促进脑胶质瘤恶性进展的研究
    • 批准号:
      --
    • 项目类别:
      面上项目
    • 资助金额:
      52万元
    • 批准年份:
      2022
    • 负责人:
      周秀萍
    • 依托单位:
    11C-N-CH3-Dopamine PET/MRI心脏神经显像对射血分数保留的心衰的实验研究
    • 批准号:
      82171969
    • 项目类别:
      面上项目
    • 资助金额:
      56万元
    • 批准年份:
      2021
    • 负责人:
      王雪梅
    • 依托单位:
    11C-N-CH3-Dopamine心肌Micro PET/CT显像对糖尿病心脏自主神经病变的评估
    • 批准号:
      82060323
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      34.0万元
    • 批准年份:
      2020
    • 负责人:
      何玉林
    • 依托单位:
    11C-N-CH3-Dopamine神经显像对心肌"缺血记忆"的实验研究
    • 批准号:
      81460271
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      46.0万元
    • 批准年份:
      2014
    • 负责人:
      王雪梅
    • 依托单位: